Randomized Trial of Buprenorphine for Treatment of Concurrent Opiate and Cocaine Dependence

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2004 Jan 30

PMID 14749690

Citations 63

Authors

Ivan D Montoya

David A Gorelick

Kenzie L Preston

Jennifer R Schroeder

Annie Umbricht

Lawrence J Cheskin

W Robert Lange

Carlo Contoreggi

Rolley E Johnson

Paul J Fudala

Affiliations

Soon will be listed here.

Abstract

Background: Buprenorphine is a partial mu-opiate agonist and kappa-opiate antagonist with established efficacy in the treatment of opiate dependence. Its efficacy for cocaine dependence is uncertain. This study evaluated buprenorphine for the treatment of concomitant cocaine and opiate dependence.

Methods: Two hundred outpatients currently dependent on both cocaine and opiates were randomly assigned to double-blind groups receiving a sublingual solution of buprenorphine (2, 8, or 16 mg daily, or 16 mg on alternate days, or placebo), plus weekly individual drug abuse counseling, for 13 weeks. The chief outcome measures were urine concentrations of opiate and cocaine metabolites (quantitative) and proportion of urine samples positive for opiates or cocaine (qualitative). Group differences were assessed by use of mixed regression modeling.

Results: The target dose of buprenorphine was achieved in 179 subjects. Subjects receiving 8 or 16 mg buprenorphine daily showed statistically significant decreases in urine morphine levels (P =.0135 for 8 mg and P <.001 for 16 mg) or benzoylecgonine concentrations (P =.0277 for 8 mg and P =.006 for 16 mg) during the maintenance phase of the study. For the 16-mg group, mean benzoylecgonine concentrations fell from 3715 ng/mL during baseline to 186 ng/mL during the withdrawal phase; mean morphine concentrations fell from 3311 ng/mL during baseline to 263 ng/mL during withdrawal. For the 8-mg group, mean benzoylecgonine concentrations fell from 6761 ng/mL during baseline to 676 ng/mL during withdrawal; mean morphine concentrations fell from 3890 ng/mL during baseline to 661 ng/mL during withdrawal. Qualitative urinalysis showed a similar pattern of results. Subjects receiving the highest dose showed concomitant decreases in both urine morphine and benzoylecgonine concentrations. There were no significant group differences in treatment retention or adverse events.

Conclusions: A sublingual buprenorphine solution at 16 mg daily is well tolerated and effective in reducing concomitant opiate and cocaine use. The therapeutic effect on cocaine use appears independent of that on opiate use.

Citing Articles

Opioidergic tuning of social attachment: reciprocal relationship between social deprivation and opioid abuse.

Galiza Soares J, Sutley-Koury S, Pomrenze M, Tucciarone J Front Neuroanat. 2025; 18:1521016.

PMID: 39917739 PMC: 11798945. DOI: 10.3389/fnana.2024.1521016.

Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings.

Hooker S, Starkey C, Bart G, Rossom R, Kane S, Olson A BMC Prim Care. 2024; 25(1):361.

PMID: 39394565 PMC: 11468455. DOI: 10.1186/s12875-024-02609-9.

IUPHAR Review: New strategies for medications to treat substance use disorders.

Montoya I, Volkow N Pharmacol Res. 2024; 200:107078.

PMID: 38246477 PMC: 10922847. DOI: 10.1016/j.phrs.2024.107078.

Trends in buprenorphine dosage and days supplied for new treatment episodes for opioid use disorder, 2010-2019.

Tilhou A, Murray E, Wang J, Linas B, White L, Samet J Drug Alcohol Depend. 2023; 252:110981.

PMID: 37839942 PMC: 10615721. DOI: 10.1016/j.drugalcdep.2023.110981.

Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder.

Lier A, Vander Wyk B, Di Paola A, Springer S Open Forum Infect Dis. 2022; 9(11):ofac624.

PMID: 36467300 PMC: 9709708. DOI: 10.1093/ofid/ofac624.

References

Petitjean S, Stohler R, Deglon J, Livoti S, Waldvogel D, Uehlinger C . Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 2001; 62(1):97-104. DOI: 10.1016/s0376-8716(00)00163-0. View

Mallinckrodt C, Clark W, David S . Accounting for dropout bias using mixed-effects models. J Biopharm Stat. 2001; 11(1-2):9-21. DOI: 10.1081/BIP-100104194. View

Naumova E, Must A, Laird N . Tutorial in Biostatistics: Evaluating the impact of 'critical periods' in longitudinal studies of growth using piecewise mixed effects models. Int J Epidemiol. 2002; 30(6):1332-41. DOI: 10.1093/ije/30.6.1332. View

Leri F, Bruneau J, Stewart J . Understanding polydrug use: review of heroin and cocaine co-use. Addiction. 2002; 98(1):7-22. DOI: 10.1046/j.1360-0443.2003.00236.x. View

Oliveto A, FEINGOLD A, Schottenfeld R, Jatlow P, Kosten T . Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Arch Gen Psychiatry. 2003; 56(9):812-20. DOI: 10.1001/archpsyc.56.9.812. View

Babst D, Chambers C, Warner A . Patient characteristics associated with retention in a methadone maintenance program. Br J Addict Alcohol Other Drugs. 1971; 66(3):195-204. DOI: 10.1111/j.1360-0443.1971.tb02386.x. View

Brown B, DuPont R, Bass 3rd U, Brewster G, Glendinning S, Kozel N . Impact of a large-scale narcotics treatment program: a six month experience. Int J Addict. 1973; 8(1):49-57. DOI: 10.3109/10826087309048763. View

DeRogatis L, Cleary P . Factorial invariance across gender for the primary symptom dimensions of the SCL-90. Br J Soc Clin Psychol. 1977; 16(4):347-56. DOI: 10.1111/j.2044-8260.1977.tb00241.x. View

McLellan A, Luborsky L, Woody G, OBrien C . An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980; 168(1):26-33. DOI: 10.1097/00005053-198001000-00006. View

10.

ROBINS L, Helzer J, Ratcliff K, Seyfried W . Validity of the diagnostic interview schedule, version II: DSM-III diagnoses. Psychol Med. 1982; 12(4):855-70. DOI: 10.1017/s0033291700049151. View

11.

Rounsaville B, Gawin F, Kleber H . Interpersonal psychotherapy adapted for ambulatory cocaine abusers. Am J Drug Alcohol Abuse. 1985; 11(3-4):171-91. DOI: 10.3109/00952998509016860. View

12.

Kosten T, KLEBER H, Morgan C . Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci. 1989; 44(13):887-92. DOI: 10.1016/0024-3205(89)90589-4. View

13.

Mello N, MENDELSON J, Bree M, Lukas S . Buprenorphine suppresses cocaine self-administration by rhesus monkeys. Science. 1989; 245(4920):859-62. DOI: 10.1126/science.2772637. View

14.

Kosten T, KLEBER H, Morgan C . Treatment of cocaine abuse with buprenorphine. Biol Psychiatry. 1989; 26(6):637-9. DOI: 10.1016/0006-3223(89)90090-5. View

15.

Hser Y, Anglin M, Liu Y . A survival analysis of gender and ethnic differences in responsiveness to methadone maintenance treatment. Int J Addict. 1990; 25(11A):1295-315. DOI: 10.3109/10826089009068465. View

16.

Mello N, Lukas S, Kamien J, MENDELSON J, Drieze J, Cone E . The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J Pharmacol Exp Ther. 1992; 260(3):1185-93. View

17.

Johnson R, Jaffe J, Fudala P . A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992; 267(20):2750-5. View

18.

Carrieri M, Vlahov D, Dellamonica P, Gallais H, Lepeu G, Spire B . Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. Drug Alcohol Depend. 2000; 60(1):51-4. DOI: 10.1016/s0376-8716(99)00136-2. View

19.

de los Cobos J, Martin S, Etcheberrigaray A, Trujols J, Batlle F, Tejero A . A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug Alcohol Depend. 2000; 59(3):223-33. DOI: 10.1016/s0376-8716(99)00122-2. View

20.

Amass L, Kamien J, Mikulich S . Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend. 2000; 58(1-2):143-52. DOI: 10.1016/s0376-8716(99)00074-5. View